LONG-TERM SAFETY AND EFFICACY OF CANAKINUMAB VS TRIAMCINOLONE ACETONIDE IN PATIENTS WITH FREQUENT ACUTE GOUTY ARTHRITIS ATTACKS WHO ARE CONTRAINDICATED, INTOLERANT OR UNRESPONSIVE TO NSAIDS AND/OR COLCHICINE

被引：1
|
作者：
Alten, R.
Schlesinger, N. [1 ]
So, A. [2 ]
Schumacher, H. R. [3 ,4 ]
Bloch, M. T. [5 ]
Machein, U. [6 ]
Richard, D. [6 ]
Lheritier, K. [6 ]
Bardin, T. [7 ]
机构：
[1] Rutgers RWJMS, New Brunswick, NJ USA
[2] CHU Vaudois, Serv Rhumatol, Lausanne, Switzerland
[3] Univ Penn, Philadelphia, PA 19104 USA
[4] VA Med Ctr, Philadelphia, PA USA
[5] Holdsworth House Med Practice, Sydney, NSW, Australia
[6] Novartis Pharma AG, Basel, Switzerland
[7] Hop Lariboisiere, F-75475 Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1807
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0537
引用
收藏
页码：785 / 785
页数：1
相关论文
共 41 条
  • [31] LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): 5-YEAR FOLLOW-UP OF AN OPEN-LABEL TRIAL
    Ruperto, N.
    Brunner, H. I.
    Quartier, P.
    Constantin, T.
    Alexeeva, E.
    Schneider, R.
    Kone-Paut, I.
    Schikler, K.
    Marzan, K.
    Wulffraat, N.
    Padeh, S.
    Chasnyk, V.
    Wouters, C.
    Kuemmerle-Deschner, J. B.
    Kallinich, T.
    Lauwerys, B.
    Haddad, E.
    Nasonov, E.
    Trachana, M.
    Vougiouka, O.
    Leon, K.
    Speziale, A.
    Lheritier, K.
    Martini, A.
    Lovell, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 265 - 266
  • [32] Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al
    Ozen, Seza
    De Benedetti, Fabrizio
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
  • [33] Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)
    Aletaha, Daniel
    Bingham, Clifton O.
    Karpouzas, George Athanasios
    Takeuchi, Tsutomu
    Thorne, Carter
    Bili, Androniki
    Agarwal, Prasheen
    Hsu, Benjamin
    Rao, Ravi
    Brown, Kurt
    Tanaka, Yoshiya
    RMD OPEN, 2021, 7 (01):
  • [34] Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
    Genovese, Mark C.
    Fleischmann, Roy
    Tanaka, Yoshiya
    Furst, Daniel E.
    Yamanaka, Hisashi
    Joshi, Rajesh
    Zhu, Wei
    Shao, Jing
    Mashimo, Hideki
    Takeuchi, Tsutomu
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] Long-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis who had failed or were intolerant to oral nonsteroidal immunosuppressants: pooled analysis of JADE clinical trials
    Ardern-Jones, M.
    Ameen, M.
    de Bruin-Weller, M.
    Simpson, E.
    Chiu, W. S.
    Biswas, P.
    Chan, G.
    Koulias, C.
    Weidinger, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E151 - E152
  • [36] Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
    de Botton, Stephane
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Riva, Marta
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Gianolio, Diego A.
    Patel, Prapti
    Recher, Christian
    Doehner, Hartmut
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S304 - S304
  • [37] Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
    Gladman, Dafna D.
    Nash, Peter
    Mease, Philip J.
    Fitzgerald, Oliver
    Duench, Stephanie
    Cadatal, Mary Jane
    Masri, Karim R.
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [38] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 725 - 733
  • [39] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
    Gladman, Dafna
    Nash, Peter
    Mease, Philip J.
    FitzGerald, Oliver
    Masri, Karim R.
    Duench, Stephanie
    Jane Cadatal, Mary
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801
  • [40] SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULT FROM LONG-TERM, INTERVENTIONAL, OPEN LABEL EXTENSION STUDY IN PATIENTS FROM POLAND AND RUSSIA WHO COMPLETED THE GLOBAL, MULTINATIONAL TRIAL (CHERISH STUDY)
    Opoka-Winiarska, V.
    Smolewska, E.
    Zuber, Z.
    Debowska, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 394 - 394
12345